[Immunohistochemical results obtained with bromodeoxy uridine (BUdR) labelled tumors of the head and neck].
In a prospective study 17 patients with oral PE carcinoma were given bolus injections of a non-toxic dose of BUdR, 4 hours prior to tumor surgery. BUdR replaces thymidine in the DNA of those cells which are in the S phase at the time of application. The resected tumor material was fixed in formalin and embedded in paraffin for immunohistochemical analysis using a monoclonal antibody against BUdR incorporated in DNA. The BUdR-storing cells were evaluated in 4 histologically different tumor areas. A total of 1600 cells was evaluated in each primary tumor or, in given cases, each lymph node metastasis or recurrence. In contrast to flow cytometry, this morphological method proved useful not only in comparing the number of BUdR-labelled cells with the total tumor cell population in different carcinoma segments, but also in correlating the focal proliferation tendency with the regional degree of differentiation and the number of mitotic cells even in morphologically different tissue segments. More often than not these results showed an increase in the average BUdR storage rate with increasing dedifferentiation and increasing rate of mitosis. Nevertheless, this is not the rule for each individual case. Some tumors displayed a relatively high proliferation tendency and BUdR storage rate in more highly differentiated areas (marked keratinization). Some poorly differentiated tumors or tumor areas, on the other hand, exhibited relatively low storage rates. Possibly, immunohistochemical analysis of a biopsy specimen after preoperative BUdR application may provide information on the radiosensitivity of the tumor.(ABSTRACT TRUNCATED AT 250 WORDS)
Radner
H
H
Institut für Pathologische Anatomie der Universität Graz.
Kärcher
H
H
D001973:Bromodeoxyuridine; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000473:pathology*; D002455:Cell Division; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D009062:Mouth Neoplasms / Q000175:diagnosis / Q000473:pathology*; D011446:Prospective Studies; D016196:S Phase
D001973:Bromodeoxyuridine
Immunhistochemische Ergebnisse von Bromodeoxyuridin (BUdR)-markierten Tumoren des Kopf-Hals-Bereiches.